JO
SGTX

John Overdeck’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

John Overdeck’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,197
Closed -$23K – 3096
2022
Q1 		$23K Sell
1,197
-1,269
-51% -$28.3K ﹤0.01% 2523
2021
Q4 		$88K Buy
+2,466
New +$140K ﹤0.01% 4080
2021
Q3 		– Sell
-2,522
Closed -$352K – 4879
2021
Q2 		$352K Buy
+2,522
New +$443K ﹤0.01% 3376

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

John Overdeck's SGTX Position: Q2 2022 in Review

John Overdeck sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 1,197 shares — an estimated $23K sold.

John Overdeck first reported a position in SGTX in Q2 2021 and held it in 3 quarters. The position peaked at $352K in Q2 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

  • John Overdeck reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • John Overdeck sold 1,197 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $23K.
  • John Overdeck first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • John Overdeck's Sigilon Therapeutics, Inc. Common Stock position peaked at $352K in Q2 2021.
  • 37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Two Sigma Investments's 13F filing for Q2 2022, filed 15 Aug 2022.